Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. But recent research has concluded that Eprin (EPH) B2 seems to play an important role in malignant pleural mesothelioma cell lines and tumors.
The FDA has granted orphan drug designation to a cancer stem cell inhibitor known as VS-6063, or defactinib, for use in the treatment of mesothelioma, a rare form of lung cancer.
A large UK study found a wide variation between cancer types in patients who had visited their general practitioner 3 or more times before cancer diagnosis.
Lung-sparing surgery combined with photodynamic therapy (PDT) improved overall survival in patients with pleural mesothelioma compared with those treated with conventional therapy and PDT.
Temsirolimus, a kinase inhibitor commonly used to treat advanced renal cell carcinoma, may increase the effectiveness of chemotherapy administered in the treatment of mesothelioma.
